Rhythm Pharmaceuticals News and Activities

Rhythm Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Rhythm Pharmaceuticals is a company listed under the stock ticker RYTM (US).

View the org chart displaying its 43 main executives

Most searched biographies at Rhythm Pharmaceuticals

• David Meeker, Chairman of Board, President and Chief Executive Off...
• Stuart Arbuckle, Director
• Christophe Jean, Director

Popular executive movements at Rhythm Pharmaceuticals

• Kim Popovits has joined the company as Director  (posted on April 3 2026).
• Ed Mathers, Lead Independent Director, has left the company  (posted on April 3 2026).
• Andrea Dipalma, who was Associate Director, Marketing and Field Operations, is promoted to Director, Marketing & Field Operations  (posted on April 3 2026).

Click here to view some more movements at Rhythm Pharmaceuticals

Create your alert
to follow the executive moves at Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Rhythm Pharmaceuticals

• Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals to Present at Investor Conferences in September | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
• Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers | Rhythm Pharmaceuticals, Inc.
• View more press releases Close

Social media about Rhythm Pharmaceuticals

• Rhythm Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Rhythm Pharmaceuticals on LinkedIn, X (Twitter) & YouTube